Evidence supporting the use of: Brown Seaweed (unspecified)
For the health condition: Thrombosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Brown seaweed, particularly species such as Laminaria and Fucus, contains bioactive compounds like fucoidan, alginate, and laminarin. There is emerging scientific interest in the potential antithrombotic (anti-blood clotting) effects of these compounds. Preclinical studies, especially in vitro and in animal models, suggest that fucoidan—a sulfated polysaccharide—can inhibit platelet aggregation and modulate coagulation pathways. Some studies have reported that fucoidan can prolong activated partial thromboplastin time (aPTT) and reduce thrombus formation in animal models, likely through mechanisms similar to those of heparin, a standard anticoagulant drug.

However, the clinical evidence in humans is limited. There are no large-scale, high-quality clinical trials directly testing brown seaweed or its extracts for the treatment or prevention of thrombosis in humans. The bulk of evidence comes from laboratory and animal studies, and while these are promising, they are not sufficient to confidently recommend brown seaweed for thrombosis management at this time. Furthermore, safety, dosing, and efficacy in humans remain unclear.

In summary, while there is some scientific basis from preclinical research suggesting brown seaweed constituents may have antithrombotic properties, the evidence is preliminary and not yet validated in human clinical use. Thus, the evidence rating is moderate but not strong.

More about Brown Seaweed (unspecified)
More about Thrombosis

Products containing Brown Seaweed (unspecified)

We currently have no products on Caring Sunshine that contain this ingredient.